Who should not use peptides: clinical contraindications

Most peptide therapy is generally well-tolerated under physician supervision — but not for everyone, and the screening exists for good reasons.

TL;DR

• People with active cancer, pregnancy, or unstable serious illness are typically excluded from peptide therapy.
• Some peptides raise IGF-1, which clinicians screen for before prescribing growth-hormone-related compounds.
• A licensed clinician makes the final call after reviewing your history, labs, and current medications.

What it is

A contraindication is a medical reason not to use a treatment. For peptides, contraindications come from two places: known side-effect profiles in published literature, and the cautious assumption that what hasn’t been studied in a population shouldn’t be used in that population. The list isn’t long, but it matters. The most common categories are pregnancy, recent cancer, severe untreated illness, and certain endocrine conditions.

How it works

Most peptides act like signaling keys. They fit a specific receptor and turn on (or up) a pathway your body already uses. That precision is part of what makes them useful — but it also means a peptide that signals growth or repair could, in theory, signal the wrong cells in someone with active cancer. The IGF-1 question (in plain English: a growth-promoting hormone that growth-hormone peptides raise) is the central concern with secretagogues like CJC-1295 and sermorelin.

Who asks about it

People come to this topic when they have a complex medical history and want to know whether peptides are off the table. Cancer survivors, people on multiple medications, and those with autoimmune or endocrine conditions are common in this group. The honest answer is: it depends on your case, and a clinician needs to walk through it with you.

What the research says

Published guidance on peptide use is limited because most peptides are studied in healthy adults. Growth hormone secretagogue trials excluded patients with active malignancy, uncontrolled diabetes, and severe organ disease. Pregnancy and lactation are universal exclusion criteria across peptide trials. Patients with prolactinoma or untreated thyroid disease are also commonly excluded.

What to know before considering it

Peptide therapy requires a clinician evaluation. If you have a history of cancer (especially within the last five years), are pregnant or nursing, take immunosuppressants, or have an unstable serious illness, expect a longer screening conversation. The goal isn’t to gatekeep — it’s to make sure the protocol fits your real situation.

The Halftime POV

We screen because the alternative is sloppy. A clinic that prescribes peptides without asking about cancer history, pregnancy status, or current medications isn’t being efficient — it’s being careless. Good medicine takes the extra ten minutes.

Related reading:

• What are peptides? A plain-English primer
• How to have a goals-first conversation with your clinician
• Biomarkers commonly tracked during peptide protocols

FAQ

Q: Who should not use peptides? A: People with active or recent cancer, pregnancy, untreated severe illness, or unstable conditions are typically screened out. A licensed clinician decides on a case-by-case basis.

Q: Are peptides safe during pregnancy? A: No. Pregnant and nursing patients are excluded from peptide therapy because most compounds have not been studied for use during pregnancy or lactation.

Q: Can peptides be used with cancer history? A: Growth hormone peptides raise IGF-1, which has theoretical concerns in active cancer. Patients with cancer history should only consider peptides after oncologist review.

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.

Sources

• Clemmons DR. Safety of growth hormone secretagogues. (PubMed, 2018)
• FDA. Human Drug Compounding overview. (FDA.gov)

This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health’s published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.